June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Comparison of outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in exudative Age-related Macular Degeneration (AMD) in the presence and absence of Vitreomacular Adhesion (VMA)
Author Affiliations & Notes
  • Seena Nambiar
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
  • Manju Chandran
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
  • Narendran Nair
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
  • Sidharth Praveen
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
  • Malpreet Lidder
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
  • Geeta Menon
    Ophthalmology, Frimley Park Hospital, Surrey, United Kingdom
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3830. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seena Nambiar, Manju Chandran, Narendran Nair, Sidharth Praveen, Malpreet Lidder, Geeta Menon; Comparison of outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in exudative Age-related Macular Degeneration (AMD) in the presence and absence of Vitreomacular Adhesion (VMA). Invest. Ophthalmol. Vis. Sci. 2013;54(15):3830.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the outcome of anti-VEGF treatment in exudative AMD in the presence and absence of VMA.

Methods: We retrospectively analysed medical records and Optical Coherence Tomography (OCT) scans of 38 patients (38 eyes) who were receiving intravitreal injections of Ranibizumab for exudative AMD. We included 19 patients in Group A (presence of VMA) and 19 patients in the control Group B (no VMA). Both groups were comparable in respect of age distribution, Best Corrected Visual Acuity (BCVA) and central macular thickness (CMT) at baseline. BCVA and CMT were compared between the two groups at baseline and at 12 months

Results: Mean BCVA (ETDRS letters) in Group A at baseline was 57.79 and showed a statistically significant improvement at 12 months by 8.74 letters (P= 0.043). In Group B there was a significant improvement in BCVA from baseline 59.47 over 12 months by 8.16 letters (P=0.040). Baseline CMT in Group A was 315.11microns and showed a significant reduction by 62.27 microns (P=0.016), and Group B showed a reduction in CMT from baseline of 310.48microns by 54.89 microns (P=0.022) at 12 months review.

Conclusions: Our results with a small number of patients showed both groups responded equally well to the anti-VEGF treatment. Presence of vitreomacular adhesion in wet macular degeneration did not seem to affect the response to anti-VEGF treatment, and prompt treatment on diagnosis helps to achieve better visual outcome. Further prospective studies with larger groups of patients over a longer period are needed to fully evaluate if presence of VMA is an indicator for poor response to anti-VEGF treatment in wet AMD.

Keywords: 412 age-related macular degeneration • 754 visual acuity • 763 vitreous  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×